[Merck's $11.3B biotech acquisition](https://www.cnbc.com/2026/06/25/germanys-merck-kgaa-to-buy-bio-techne.html) is being spun as strategic growth, but here's what it actually signals: management doesn't believe it can generate adequate returns through R&D and existing pipelines. Large-cap pharma paying up for high-growth biotech is the textbook move when ROIC is rolling over and organic innovation has stalled. The real question isn't whether Bio-Techne's tech is good—it probably is.